Man Group
ACRS icon

Man Group’s Aclaris Therapeutics ACRS Stock Holding History

Man Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-42,435
Closed -$128K – 2370
2025
Q4 		$128K Buy
+42,435
New +$107K ﹤0.01% 2172
2025
Q2 		– Sell
-197,748
Closed -$303K – 2153
2025
Q1 		$303K Buy
197,748
+144,214
+269% +$308K ﹤0.01% 1933
2024
Q4 		$133K Buy
+53,534
New +$133K ﹤0.01% 1911
2024
Q3 		– Sell
-118,459
Closed -$130K – 1948
2024
Q2 		$130K Sell
118,459
-129,216
-52% -$152K ﹤0.01% 1939
2024
Q1 		$307K Buy
247,675
+146,395
+145% +$175K ﹤0.01% 1932
2023
Q4 		$106K Buy
+101,280
New +$309K ﹤0.01% 1976
2023
Q3 		– Sell
-133,036
Closed -$1.14M – 1439
2023
Q2 		$1.38M Buy
+133,036
New +$1.2M ﹤0.01% 1297
2023
Q1 		– Hold
0
– – – 1635
2020
Q3 		– Sell
-93,518
Closed -$151K – 1768
2020
Q2 		$151K Hold
93,518
– – ﹤0.01% 1612
2020
Q1 		$97K Sell
93,518
-1,202,448
-93% -$1.64M ﹤0.01% 1518
2019
Q4 		$2.45M Sell
1,295,966
-2,438,827
-65% -$4.04M 0.01% 1275
2019
Q3 		$4.03M Buy
3,734,793
+1,676,857
+81% +$2.38M 0.02% 969
2019
Q2 		$4.51M Buy
2,057,936
+872,408
+74% +$4.76M 0.02% 992
2019
Q1 		$7.1M Buy
1,185,528
+519,098
+78% +$3.44M 0.03% 741
2018
Q4 		$4.92M Buy
666,430
+263,806
+66% +$2.72M 0.02% 773
2018
Q3 		$5.85M Buy
402,624
+321,458
+396% +$5.51M 0.02% 902
2018
Q2 		$1.62M Buy
+81,166
New +$1.5M 0.01% 1446

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Man Group's ACRS Position: Q1 2026 in Review

Man Group sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 42,435 shares — an estimated $128K sold.

Man Group first reported a position in ACRS in Q2 2018 and held it in 16 quarters. The position peaked at $7.1M in Q1 2019. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Man Group reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Man Group sold 42,435 Aclaris Therapeutics shares in Q1 2026, an estimated $128K.
  • Man Group first reported a position in Aclaris Therapeutics in Q2 2018 and held it in 16 quarters.
  • Man Group's Aclaris Therapeutics position peaked at $7.1M in Q1 2019.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.